Aline Diogo Marinho

Aline Diogo Marinho

Federal University of Ceara, Brazil

Title: Hyperglycemia Associated With Kidney Transplantation: Clinical And Possible Risk Factors


Bachelor's at Pharmacy from Federal University of Ceara- UFC (2011) and master's at Pharmacology at the age of 27 from School of Medicine, UFC (2013). Scholarship student of CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and doctoral studentin Pharmacology from UFC since 2014. Has experience in pharmacology, with emphasis on renal pharmacology, focusing in the following topics: toxinology, venoms and renal alterations. Member of Laboratory of Pharmacology of Venoms, Toxins and Lectins (LAFAVET).


The hyperglycemia associated with transplantation (HAT) is associated with worse patient survival outcomes and renal graft. The aim of this study was to evaluate clinical features and risk factors for the development of hyperglycemia after renal transplantation in a university hospital (Fortaleza / Ceará). This is a retrospective cohort study of kidney transplant patients from July 2012 to July 2013. All 121 transplant patients in this period were selected for the study, 37 patients were excluded for: transfer to another transplant center, death, loss graft, pre-transplant diabetes mellitus or double transplantation during the study. The 84 patients were divided into 3 groups according to glycemic status (normal glycemic, pre-diabetics and diabetics) and parameters were analyzed in laboratory during the period of 1 year post-transplant and hypoglycemic agents used within 2 years after transplantation. Advanced age was the risk factor that had a significant association with hyperglycemia (p <0.05). The percentage of diabetic patients was found to be 8.3% (n = 7) and pre-diabetic 48.8% (n = 41). In the study 14 patients used glucose-lowering drug therapy (oral and / or injectable), being 8 (57.1%) patients in pre-diabetic group and 6 (42.9%) of the diabetic group, with the median time to onset treatment of 216 days, median of 47 days and range from 12-692 days, and hypoglycemic metformin more frequent. The hyperglycemia associated with renal transplantation has a strong relationship with older, so older individuals need more intensive monitoring of glycemic parameters.